Clinical and laboratory features of hepatocellular carcinoma by Andrés Cárdenas, María C. Londoño

“…</span></p> <p class="MsoNormal"><span style="font-size: 10pt; font-family: QuorumITCbyBT-Book">• Erythrocytosis may be due to the production of erythropoietin by the tumor. Although, 23% of the patients with hepatocellular carcinoma have this abnormality, elevations in hemoglobin concentration are uncommon.…”
Get full text

Withdrawal of renin-angiotensin system inhibitors’ effect on estimated glomerular filtration rate in adults with advanced kidney disease: the STOP-ACEi RCT by Sunil Bhandari, Samir Mehta, Arif Khwaja, John Cleland, Natalie Ives, Elizabeth Brettell, Marie Chadburn, Paul Cockwell

“…Discontinuation of ACEi/ARB affects the requirement for erythropoietin stimulating agents. Methods An investigator-initiated, multicentre, open-label randomised trial where people with advanced and progressive CKD (eGFR < 30 ml/minute/1.73 m2) were randomised to either discontinue or continue RAS inhibitors, and then followed up every 3 months for 3 years. …”
Get full text

Selected Abstracts of the 9th International Workshop on Neonatology; Cagliari (Italy); October 23-26, 2013 by --- Various Authors

“…Örs; Konya (Turkey) ABS 41. Erythropoietin adiministration effetcs on heart in Landrace/Large White pigs exposed to ventricular fibrillation • A. …”
Get full text

Selected Abstracts of the 1st Congress of joint European Neonatal Societies (jENS 2015); Budapest (Hungary); September 16-20, 2015; Session “Brain & Development” by --- Various Authors

“…NEURODEVELOPMENTAL OUTCOME AFTER EARLY HIGH DOSE RECOMBINANT HUMAN ERYTHROPOIETIN IN VERY PRETERM INFANTS: RESULTS OF A RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL • G. …”
Get full text

HIF-1 and HIF-2: working alone or together in hypoxia? by Ratcliffe, P

“…Erythropoietin (EPO) is the hormonal regulator of red cell production and provided the paradigm for oxygen-regulated gene expression that led to the discovery of hypoxia-inducible factor (HIF). …”

Intraocular Sustained Release of EPO-R76E Mitigates Glaucoma Pathogenesis by Activating the NRF2/ARE Pathway by Sarah Naguib, Carlisle R. DeJulius, Jon R. Backstrom, Ameer A. Haider, John M. Ang, Andrew M. Boal, David J. Calkins, Craig L. Duvall, Tonia S. Rex

“…Erythropoietin (EPO) is neuroprotective in multiple models of neurodegenerative diseases, including glaucoma. …”
Get full text

Therapeutic efficacy of erythrpoietin in experimental autoimmune encephalomyelitis in mice, a model of multiple sclerosis by Cervellini, I, Ghezzi, P, Mengozzi, M

“…Erythropoietin (EPO) has neuroprotective effects in many models of damage and disease of the nervous system where neuroinflammation plays a substantial role, including experimental autoimmune encephalomyelitis (EAE), the animal model of multiple sclerosis (MS). …”

Anemia and iron deficiency in cancer patients: the role of intravenous iron supplements (a literature review) by Dina D. Sakaeva

“…Current therapy for anemia in malignant tumors includes replacement therapy with an iron supplement, erythropoiesis-stimulating agents (erythropoietins), and blood transfusions. However, blood transfusions should be minimized due to the high risks and costs. …”
Get full text

Dyserythropoiesis dans la trypanosomose animale by I.O. Igbokwe

“…Les raisons de la dysérythropoïèse ne sont cependant pas claires mais peuvent être associées à un trouble érythrocytaire, à une synthèse ralentie ou insuffisante de l'érythropoïétine, à une baisse de la synthèse de l'hémoglobine, ou à une combinaison interréactionnelle de ces facteurs. …”
Get full text

Clinical relevance and treatment of nonautoimmune anemia in chronic lymphocytic leukemia by Molica S, Mirabelli R, Molica M,&amp;nbsp;Levato L, Mauro F, Fo&amp;agrave; R

“…Finally, the increasing use of aggressive approaches to therapy should encourage physicians towards appropriate management of chemotherapy-induced anemia in CLL patients.Keywords: anemia, chronic lymphocytic leukemia, erythropoietin…”
Get full text

Classification of anemia as to the medullary response through reticulocyte count in dogs attended to in the Veterinary Hospital from Federal University of Mato Grosso, Campus Sinop... by D. B. Morais, M. S. Jesus, A. C. Bonatto, D. W. Silva, A. Kataoka

“…In conclusion, in this study was observed a predominance of non-regenerative anemia and a lower incidence of responsive anemia; the medullary response was more evident in hemoparasitosis anemia and non-regenerative anemia occurred mainly in animals with renal insufficiency, possibly due to insufficient production of erythropoietin…”
Get full text

The positive effect of JAK inhibitor tofacitinib in the treatment of primary Sjögren’s syndrome: a clinical case by D.G. Rekalov, I.O. Daniuk

“…The perspective group for the treatment of autoimmune disease is Janus kinase inhibitors, which can block the signals from biologically active molecules (interferons, erythropoietins and cytokines) and providing a response to these target cell signals. …”
Get full text

Safety of biological preparations. Report 1. Terminology and classification issues by A. A. Soldatov, Zh. I. Avdeeva, Yu. V. Olefir, V. A. Merkulov, V. P. Bondarev

“…The mentioned classification method has certain disadvantages: it does not cover all biological preparations, but only drugs, containing cytokines, hormones and monoclonal antibodies preparations; and it does not consider ADR occurring without immune mechanisms (such as increased blood pressure when administering preparations of recombinant erythropoietins).…”
Get full text

Drug utilization in patients starting haemodialysis with a focus on cardiovascular and antidiabetic medications: an epidemiological study in the Lazio region (Italy), 2016–2020 by Ursula Kirchmayer, Claudia Marino, Sandro Feriozzi, Carlo Massimetti, Micol Manzuoli, Laura Angelici, Anna Maria Bargagli, Silvia Cascini, Antonio Addis, Marina Davoli, Nera Agabiti

“…Dialysis-specific therapies showed the most evident increase, in particular anti-anaemics (iron 4-fold, erythropoietins almost 2-fold), anti-parathyroids (6-fold), and chelating agents (4-fold). …”
Get full text

COST-MINIMIZATION ANALYSIS OF USING SHORT AND LONG-ACTING ERYTHROPOESIS-STIMULATING AGENTS FOR CORRECTION OF NEPHROGENIC ANEMIA AGAINST THE BACKGROUND OF SUBSTITUTION THERAPY by I. S. Krysanov, E. Yu. Ermakova, L. B. Vaskova, M. V. Tiapkina

“…Clinical trials conducted in various countries indicate that the use of epoetin alfa in patients with nephrogenic anemia in chronic kidney disease can increase the effectiveness of treatment, reduce the incidence of cardiovascular and infectious complications, and reduce mortality in patients with chronic kidney disease.The aim of the article was to conduct a comparative clinical and economic assessment of the treatment costs of nephrogenic anemia in adult dialysis patients with recombinant human erythropoietins: epoetin alfa, darbepoetin and long-acting methoxy polyethylene glycol – epoetin beta.Materials and methods. …”
Get full text

El modelo de control de anemia: ¿ayuda al nefrólogo en la decisión terapéutica para el manejo de la anemia? by María Laura Bucalo, Carlo Barbieri, Susana Roca, Jasmine Ion Titapiccolo, Maria Soledad Ros Romero, Rosa Ramos, Mercedes Albaladejo, Diana Manzano, Flavio Mari, Manuel Molina

“…Palabras clave: Anemia, Inteligencia artificial, Enfermedad renal crónica, Hemodiálisis, Agentes estimulantes de la eritropoyesis, Eritropoyetina, Keywords: Anaemia, Artificial intelligence, Chronic kidney disease, Haemodialysis, Erythropoiesis-stimulating agents, Erythropoietin…”
Get full text